Cytek Biosciences Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 54 minutes ago
0mins
Should l Buy CTKB?
Source: seekingalpha
- Revenue Growth: Q1 2026 revenue reached $44.1 million, reflecting a 6% year-over-year increase, indicating a recovery in U.S. market conditions and ongoing growth in APAC (excluding China), showcasing the company's competitive position in the market rebound.
- Service and Reagent Revenue: Service revenue grew 15% to $15.4 million, accounting for 35% of total revenue, while reagent revenue also saw mid-teens growth, highlighting the company's strong performance in recurring revenue, which enhances future financial stability.
- Geographic Performance Disparities: U.S. revenue hit $24.4 million, up 32%, while EMEA revenue declined 7% due to disruptions from the Middle East conflict and shipment delays, indicating the impact of geopolitical factors on business and the need to monitor future market volatility.
- 2026 Outlook: The company reaffirmed its full-year 2026 revenue guidance of $205 million to $212 million, anticipating continued growth in services and reagents while factoring in potential macro risks, reflecting management's cautiously optimistic outlook for the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTKB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTKB
Wall Street analysts forecast CTKB stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.940
Low
5.00
Averages
6.17
High
7.50
Current: 4.940
Low
5.00
Averages
6.17
High
7.50
About CTKB
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cytek Biosciences Q1 2026 Earnings Call Insights
- Revenue Growth: Q1 2026 revenue reached $44.1 million, reflecting a 6% year-over-year increase, indicating a recovery in U.S. market conditions and ongoing growth in APAC (excluding China), showcasing the company's competitive position in the market rebound.
- Service and Reagent Revenue: Service revenue grew 15% to $15.4 million, accounting for 35% of total revenue, while reagent revenue also saw mid-teens growth, highlighting the company's strong performance in recurring revenue, which enhances future financial stability.
- Geographic Performance Disparities: U.S. revenue hit $24.4 million, up 32%, while EMEA revenue declined 7% due to disruptions from the Middle East conflict and shipment delays, indicating the impact of geopolitical factors on business and the need to monitor future market volatility.
- 2026 Outlook: The company reaffirmed its full-year 2026 revenue guidance of $205 million to $212 million, anticipating continued growth in services and reagents while factoring in potential macro risks, reflecting management's cautiously optimistic outlook for the future.
See More
Cytek Biosciences Reports Q1 Earnings Miss
- Earnings Miss: Cytek Biosciences reported a Q1 GAAP EPS of -$0.15, missing estimates by $0.05, indicating challenges in profitability that may affect investor confidence.
- Revenue Decline: The company's Q1 revenue of $44.1M fell short of the expected $44.3M, reflecting weak market demand that could lead to slower future growth.
- Widening Adjusted EBITDA Loss: The adjusted EBITDA loss for Q1 2026 was $9.1M, significantly higher than the $3.3M loss in Q1 2025, highlighting pressures on cost control and operational efficiency.
- Stable Cash Reserves: As of March 31, 2026, cash and marketable securities totaled $262.2M, a modest increase of $0.7M from $261.5M on December 31, 2025, indicating a cautious approach to liquidity management.
See More
Cytek (CTKB) Q4 2025 Earnings Call Transcript
See More
Cytek Biosciences Reports Record Q4 2025 Revenue and Growth Outlook
- Significant Revenue Growth: Cytek reported fourth-quarter revenue of $62.1 million for 2025, an 8% year-over-year increase, marking the highest quarterly revenue in the company's history, indicating strong performance in the Asia-Pacific and European markets.
- New Product Drive: The newly launched Cytek Aurora Evo system achieved a 21% unit growth in the fourth quarter, boosting sales in the overall Aurora category, demonstrating the company's success in innovative product offerings.
- Sustained Recurring Revenue: In 2025, recurring revenue accounted for 34% of total revenue, growing 21% year-over-year, reflecting the company's ongoing efforts to stabilize its customer base and services, enhancing revenue predictability for the future.
- Optimistic 2026 Outlook: The company anticipates revenue between $205 million and $212 million for 2026, based on improvements in the EMEA and U.S. markets and continued growth in the Asia-Pacific region, showcasing management's confidence in the future market environment.
See More
Cytek Biosciences Q4 Earnings Report Analysis
- Earnings Miss: Cytek Biosciences reported a Q4 GAAP EPS of -$0.34, missing expectations by $0.30, indicating challenges in profitability that could impact investor confidence.
- Revenue Beat: Despite the earnings miss, the company achieved revenue of $62.1 million, exceeding estimates by $3.3 million, suggesting that Cytek maintains a competitive edge in sales, potentially laying the groundwork for future growth.
- Investor Engagement: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, capturing investor interest, which may create opportunities for future financing and partnerships, thereby enhancing market trust.
- Historical Financial Context: Cytek's historical financial data provides a backdrop for analyzing its long-term performance; although the current earnings report is disappointing, past data may indicate potential recovery and growth prospects.
See More
Cytek Biosciences (CTKB) Projects $201 Million Revenue for 2025 with Q4 Growth of 8%
- Full Year Revenue Outlook: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, indicating sustained growth potential in the biosciences sector and reflecting strong market demand.
- Q4 Performance: The company projects fourth-quarter revenue of about $62 million for 2025, representing an 8% increase compared to Q4 2024, demonstrating its competitive strength in the market for products and services.
- Earnings Report Plans: Cytek plans to report its fourth-quarter financial results and provide 2026 guidance during an earnings call expected at the end of February 2026, highlighting its commitment to transparency and investor communication.
- Stock Price Reaction: Cytek Biosciences shares rose 9.7% in pre-market trading on Nasdaq, reaching $5.98, reflecting positive market sentiment regarding its earnings outlook.
See More
Cytek Biosciences Q1 2026 Earnings Call Insights
- Revenue Growth: Q1 2026 revenue reached $44.1 million, reflecting a 6% year-over-year increase, indicating a recovery in U.S. market conditions and ongoing growth in APAC (excluding China), showcasing the company's competitive position in the market rebound.
- Service and Reagent Revenue: Service revenue grew 15% to $15.4 million, accounting for 35% of total revenue, while reagent revenue also saw mid-teens growth, highlighting the company's strong performance in recurring revenue, which enhances future financial stability.
- Geographic Performance Disparities: U.S. revenue hit $24.4 million, up 32%, while EMEA revenue declined 7% due to disruptions from the Middle East conflict and shipment delays, indicating the impact of geopolitical factors on business and the need to monitor future market volatility.
- 2026 Outlook: The company reaffirmed its full-year 2026 revenue guidance of $205 million to $212 million, anticipating continued growth in services and reagents while factoring in potential macro risks, reflecting management's cautiously optimistic outlook for the future.
See More
Cytek Biosciences Reports Q1 Earnings Miss
- Earnings Miss: Cytek Biosciences reported a Q1 GAAP EPS of -$0.15, missing estimates by $0.05, indicating challenges in profitability that may affect investor confidence.
- Revenue Decline: The company's Q1 revenue of $44.1M fell short of the expected $44.3M, reflecting weak market demand that could lead to slower future growth.
- Widening Adjusted EBITDA Loss: The adjusted EBITDA loss for Q1 2026 was $9.1M, significantly higher than the $3.3M loss in Q1 2025, highlighting pressures on cost control and operational efficiency.
- Stable Cash Reserves: As of March 31, 2026, cash and marketable securities totaled $262.2M, a modest increase of $0.7M from $261.5M on December 31, 2025, indicating a cautious approach to liquidity management.
See More
Cytek (CTKB) Q4 2025 Earnings Call Transcript
See More
Cytek Biosciences Reports Record Q4 2025 Revenue and Growth Outlook
- Significant Revenue Growth: Cytek reported fourth-quarter revenue of $62.1 million for 2025, an 8% year-over-year increase, marking the highest quarterly revenue in the company's history, indicating strong performance in the Asia-Pacific and European markets.
- New Product Drive: The newly launched Cytek Aurora Evo system achieved a 21% unit growth in the fourth quarter, boosting sales in the overall Aurora category, demonstrating the company's success in innovative product offerings.
- Sustained Recurring Revenue: In 2025, recurring revenue accounted for 34% of total revenue, growing 21% year-over-year, reflecting the company's ongoing efforts to stabilize its customer base and services, enhancing revenue predictability for the future.
- Optimistic 2026 Outlook: The company anticipates revenue between $205 million and $212 million for 2026, based on improvements in the EMEA and U.S. markets and continued growth in the Asia-Pacific region, showcasing management's confidence in the future market environment.
See More
Cytek Biosciences Q4 Earnings Report Analysis
- Earnings Miss: Cytek Biosciences reported a Q4 GAAP EPS of -$0.34, missing expectations by $0.30, indicating challenges in profitability that could impact investor confidence.
- Revenue Beat: Despite the earnings miss, the company achieved revenue of $62.1 million, exceeding estimates by $3.3 million, suggesting that Cytek maintains a competitive edge in sales, potentially laying the groundwork for future growth.
- Investor Engagement: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, capturing investor interest, which may create opportunities for future financing and partnerships, thereby enhancing market trust.
- Historical Financial Context: Cytek's historical financial data provides a backdrop for analyzing its long-term performance; although the current earnings report is disappointing, past data may indicate potential recovery and growth prospects.
See More
Cytek Biosciences (CTKB) Projects $201 Million Revenue for 2025 with Q4 Growth of 8%
- Full Year Revenue Outlook: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, indicating sustained growth potential in the biosciences sector and reflecting strong market demand.
- Q4 Performance: The company projects fourth-quarter revenue of about $62 million for 2025, representing an 8% increase compared to Q4 2024, demonstrating its competitive strength in the market for products and services.
- Earnings Report Plans: Cytek plans to report its fourth-quarter financial results and provide 2026 guidance during an earnings call expected at the end of February 2026, highlighting its commitment to transparency and investor communication.
- Stock Price Reaction: Cytek Biosciences shares rose 9.7% in pre-market trading on Nasdaq, reaching $5.98, reflecting positive market sentiment regarding its earnings outlook.
See More
